IR-Med, Inc. Appoints Yossi Gross as CTO
Ticker: IRME · Form: 8-K · Filed: Jul 11, 2024 · CIK: 1839133
| Field | Detail |
|---|---|
| Company | Ir-Med, Inc. (IRME) |
| Form Type | 8-K |
| Filed Date | Jul 11, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, appointment, compensation
TL;DR
IR-Med just hired Yossi Gross as CTO, effective July 7th. Details on pay are vague.
AI Summary
IR-Med, Inc. announced on July 11, 2024, that its Board of Directors appointed Dr. Yossi Gross as Chief Technology Officer, effective July 7, 2024. The company also disclosed compensatory arrangements for its officers, though specific details of these arrangements were not provided in this filing.
Why It Matters
The appointment of a new CTO can signal a strategic shift or renewed focus on technological innovation and development for IR-Med, Inc.
Risk Assessment
Risk Level: medium — The filing indicates changes in officer roles and compensatory arrangements, which can introduce operational and financial risks if not managed effectively.
Key Players & Entities
- IR-Med, Inc. (company) — Filer of the 8-K report
- Yossi Gross (person) — Newly appointed Chief Technology Officer
- July 11, 2024 (date) — Date of the 8-K filing
- July 7, 2024 (date) — Effective date of Yossi Gross's appointment
FAQ
Who has been appointed as the new Chief Technology Officer for IR-Med, Inc.?
Dr. Yossi Gross has been appointed as the Chief Technology Officer for IR-Med, Inc.
When was the appointment of the new CTO effective?
The appointment of Dr. Yossi Gross as CTO was effective July 7, 2024.
What is the filing date of this 8-K report?
This 8-K report was filed on July 11, 2024.
What other information is disclosed regarding officers in this filing?
The filing also discloses compensatory arrangements of certain officers.
What is the principal executive office address for IR-Med, Inc.?
The principal executive offices are located at ZHR Industrial Zone Rosh Pina Israel.
Filing Stats: 652 words · 3 min read · ~2 pages · Grade level 12.2 · Accepted 2024-07-11 16:05:35
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex10-1.htm (EX-10.1) — 19KB
- ex10-2.htm (EX-10.2) — 18KB
- 0001493152-24-026947.txt ( ) — 250KB
- irme-20240711.xsd (EX-101.SCH) — 3KB
- irme-20240711_lab.xml (EX-101.LAB) — 33KB
- irme-20240711_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IR-Med, Inc. By: /s/ Sharon Lefkoviz Name: Sharon Lefkoviz Title: Chief Financial Officer Date: July 11, 2024